Back to mobile site

More on PGEN

- Summary
- Chart
- Profile
- Historical

Data

- Earnings
- Ratings (8.3 Score)

Upcoming Events

- Earnings (8/10/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Precigen Inc. (NQ:PGEN)
Delayed: 5.40 +0.04 (0.75%)
Prev. Close $5.36  
Open$5.43 
52 Wk High$ 
52 Wk Low$ 
Day High$5.47 
Day Low$5.37 
P/E N/A  
EPS$ 
Volume80,916 

Friends, Peers and Foes (?): ACLX, IOVA, IRON, JSPR, RVMD (more...)

Jun 15, 2026 06:41 AM Precigen receives FDA orphan drug exclusivity for PAPZIMEOS through 2032
Jun 15, 2026 06:41 AM Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
Jun 11, 2026 08:00 AM Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
Jun 2, 2026 06:57 AM H.C. Wainwright Reiterates Buy Rating on Precigen Inc. (PGEN)
Jun 1, 2026 04:29 PM Form 4 PRECIGEN, INC. For: May 28 Filed by: Thomasian Harry Jr.
Jun 1, 2026 04:29 PM Form 4 PRECIGEN, INC. For: May 28 Filed by: Tennant Phil
Jun 1, 2026 04:27 PM Form 4 PRECIGEN, INC. For: May 28 Filed by: Shah Rutul R
Jun 1, 2026 04:27 PM Form 4 PRECIGEN, INC. For: May 28 Filed by: Lehr Donald P.
Jun 1, 2026 04:26 PM Form 4 PRECIGEN, INC. For: May 28 Filed by: Sabzevari Helen
May 30, 2026 02:30 PM Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
View All Articles

Entities mentioned with PGEN

View All Entities